Physician profile
Michael E Gurule
NPI 1447398623
$1,681.76
in general payments reported to CMS, 2019-2025
12 companies · $240 in 2025
The $240 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $126 · 2021: $411 · 2022: $118 · 2023: $318 · 2024: $241 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $799.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $798.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $356.97 | 2019-2023 | Assurity |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $243.94 | 2020-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.31 | 2022-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $230.38 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $152.63 | 2021-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $136.35 | 2020-2024 | |
| E.R. Squibb & Sons, L.L.C. | $126.46 | 2019-2023 | Camzyos, Eliquis |
| Cvrx, INC. | $87.72 | 2022-2023 | Barostim Neo System |
| Amgen INC. | $40.56 | 2022-2023 | Repatha |
| Pfizer INC. | $31.13 | 2019-2021 | |
| Itamar Medical INC | $21.84 | 2025 | Watchpatone |
| Pacira Pharmaceuticals Incorporated | $16.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gurule listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.